Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models

Heart failure (HF) is a common disease in which the heart cannot meet the metabolic demands of the body. It mostly occurs in individuals 65 years or older. Cardiac transplantation is the best option for patients with advanced HF. High numbers of patient-specific cardiac myocytes (CMs) can be generat...

Full description

Bibliographic Details
Main Authors: Alexandra Bizy, Matthew Klos
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Animals
Subjects:
Online Access:https://www.mdpi.com/2076-2615/10/9/1561
id doaj-eebeb1797e7c460abc535efb1240fdd1
record_format Article
spelling doaj-eebeb1797e7c460abc535efb1240fdd12020-11-25T02:45:45ZengMDPI AGAnimals2076-26152020-09-01101561156110.3390/ani10091561Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal ModelsAlexandra Bizy0Matthew Klos1Department of Biomedical Sciences, Faculty of Health Sciences, Universidad CEU Cardenal Herrera, CEU Universities, Moncada, 46113 Valencia, SpainPediatric Cardiac and Thoracic Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USAHeart failure (HF) is a common disease in which the heart cannot meet the metabolic demands of the body. It mostly occurs in individuals 65 years or older. Cardiac transplantation is the best option for patients with advanced HF. High numbers of patient-specific cardiac myocytes (CMs) can be generated from induced pluripotent stem cells (iPSCs) and can possibly be used to treat HF. While some studies found iPSC-CMS can couple efficiently to the damaged heart and restore cardiac contractility, almost all found iPSC-CM transplantation is arrhythmogenic, thus hampering the use of iPSC-CMs for cardiac regeneration. Studies show that iPSC-CM cultures are highly heterogeneous containing atrial-, ventricular- and nodal-like CMs. Furthermore, they have an immature phenotype, resembling more fetal than adult CMs. There is an urgent need to overcome these issues. To this end, a novel and interesting avenue to increase CM maturation consists of modulating their metabolism. Combined with careful engineering and animal models of HF, iPSC-CMs can be assessed for their potential for cardiac regeneration and a cure for HF.https://www.mdpi.com/2076-2615/10/9/1561heart failurecardiac regenerationiPSC-CMsmetabolism
collection DOAJ
language English
format Article
sources DOAJ
author Alexandra Bizy
Matthew Klos
spellingShingle Alexandra Bizy
Matthew Klos
Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models
Animals
heart failure
cardiac regeneration
iPSC-CMs
metabolism
author_facet Alexandra Bizy
Matthew Klos
author_sort Alexandra Bizy
title Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models
title_short Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models
title_full Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models
title_fullStr Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models
title_full_unstemmed Optimizing the Use of iPSC-CMs for Cardiac Regeneration in Animal Models
title_sort optimizing the use of ipsc-cms for cardiac regeneration in animal models
publisher MDPI AG
series Animals
issn 2076-2615
publishDate 2020-09-01
description Heart failure (HF) is a common disease in which the heart cannot meet the metabolic demands of the body. It mostly occurs in individuals 65 years or older. Cardiac transplantation is the best option for patients with advanced HF. High numbers of patient-specific cardiac myocytes (CMs) can be generated from induced pluripotent stem cells (iPSCs) and can possibly be used to treat HF. While some studies found iPSC-CMS can couple efficiently to the damaged heart and restore cardiac contractility, almost all found iPSC-CM transplantation is arrhythmogenic, thus hampering the use of iPSC-CMs for cardiac regeneration. Studies show that iPSC-CM cultures are highly heterogeneous containing atrial-, ventricular- and nodal-like CMs. Furthermore, they have an immature phenotype, resembling more fetal than adult CMs. There is an urgent need to overcome these issues. To this end, a novel and interesting avenue to increase CM maturation consists of modulating their metabolism. Combined with careful engineering and animal models of HF, iPSC-CMs can be assessed for their potential for cardiac regeneration and a cure for HF.
topic heart failure
cardiac regeneration
iPSC-CMs
metabolism
url https://www.mdpi.com/2076-2615/10/9/1561
work_keys_str_mv AT alexandrabizy optimizingtheuseofipsccmsforcardiacregenerationinanimalmodels
AT matthewklos optimizingtheuseofipsccmsforcardiacregenerationinanimalmodels
_version_ 1724760600880349184